JD.Com Inc vs Revvity Inc — how do they compare? JD.Com Inc trades at $27.16 (market cap $36.62B), while Revvity Inc trades at $154.98 (market cap $16.98B). The key difference: JD.Com Inc is far larger — about 2.2× Revvity Inc's market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Revvity Inc for 12 Days on average.
| JD | RVTY | |
|---|---|---|
Market Cap | $36.62B | $16.98B |
Volume | 6,571,477 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $157.36 |
52-Week Low | $25.19 | $82.26 |
Typical Hold Time | 85 Days | 12 Days |
Enterprise Value | $19.26B | $19.30B |
Dividend Yield | 3.72% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $27.17, up 0.5% on the day, with strong analyst support (69.6% buy ratings) and a consensus price target of $35.86 suggesting 32% upside. Recent quarterly earnings have consistently beaten expectations, though revenue growth has slowed to 0.3% year-over-year for 2026. The stock appears fundamentally undervalued with a P/E of 17.9 and P/S of 0.2, while technical indicators show a mixed but slightly bullish bias with key support at $27.
JD offers significant valuation upside potential given its low multiples and strong cash position, but faces headwinds from slowing revenue growth and regulatory scrutiny of its European expansion. The company's robust balance sheet with $234 billion cash provides stability, though competitive pressures in Chinese e-commerce and macroeconomic concerns remain key risks for investors.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →